SEC ownership of Nanobiotix S.A.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001760854.

Comparable stake leader

Invus Global Management, LLC

Disclosed value leader

JOHNSON & JOHNSON

Comparable rows

22/22

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
22 of 22
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Invus Global Management, LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001760854
Issuer location
Paris, France

Ownership snapshot

Top shareholders of Nanobiotix S.A. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Invus Global Management, LLC
Disclosed value leader
JOHNSON & JOHNSON
Comparable rows
22/22
Latest evidence
30 Jun 2026
13D/G 13F Lead comparable stake: 9.4% 13D/G row: Invus Global Management, LLC Showing 1-8 of 22 holder rows.

Quick read

Invus Global Management, LLC leads the comparable SEC ownership view at 9.4%.

22 of 22 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Invus Global Management, LLC's linked filing trail.
Comparable ownership Top 5
Invus Global Management, LLC 9.4%
Qatar Investment Authority 7%
BAILLIE GIFFORD & CO 4.1%
JOHNSON & JOHNSON 11%
MORGAN STANLEY 0.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 22 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Invus Global Management, LLC
13D/G
Invus Public Equities, L.P.
9.4%
$193,472,946
4,828,374 shares
+$23,863,488 30 Jun 2026
Qatar Investment Authority
13D/G
7%
$133,177,657
3,532,517 shares
$0 30 Jun 2026
BAILLIE GIFFORD & CO
13D/G
4.1%
$6,142,944
1,919,670 shares
$0 31 Dec 2024
JOHNSON & JOHNSON
13F
Company
13F
11%
$212,017,863
5,623,816 shares
30 Jun 2026
MORGAN STANLEY
13F
Company
13F
0.1%
$1,877,045
49,789 shares
30 Jun 2026
JANE STREET GROUP, LLC
13F
Company
13F
0.06%
$1,213,186
32,180 shares
30 Jun 2026
HRT FINANCIAL LP
13F
Company
13F
0.05%
$1,030,000
27,332 shares
30 Jun 2026
XTX Topco Ltd
13F
Company
13F
0.03%
$597,734
15,855 shares
30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 17 Aug 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Recent insider transactions for Nanobiotix S.A.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
No insider transactions were found in the last 12 months for this issuer.
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .